

Zydus Healthcare (USA) LLC.

FINANCIAL STATEMENTS

Years Ended December 31, 2017 and 2016

RAM ASSOCIATES, CPAS

3240 East State Street Ext.

Hamilton, NJ 08619

Tel: 609 631 9552 / 609 631 9553

Fax: 888 319 8898

email: ram@ramassociates.us

ZYDUS HEALTHCARE (USA) LLC

TABLE OF CONTENTS

	<u>Page #</u>
INDEPENDENT AUDITOR'S REPORT	1
Financial Statements	
Balance Sheets as of December 31, 2017 and 2016	2
Statements of Income	
For The Years Ended December 31, 2017 and 2016.....	3
Statements of Changes in Member's Equity	
For The Years Ended December 31, 2017 and 2016	4
Statements of Cash Flows	
For The Years Ended December 31, 2017 and 2016	5
Notes to Financial Statements	6-11



CERTIFIED PUBLIC ACCOUNTANTS

FIRM FOUNDATION

MEMBER CPA

INDEPENDENT AUDITOR'S REPORT

To the members'
of Zydus Healthcare (USA) LLC.

We have audited the accompanying financial statements of Zydus Healthcare (USA) LLC., which comprise the balance sheets as of December 31, 2017 and 2016, and the related statements of income, retained earnings, and cash flows for the years then ended, and the related notes to financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatements.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design the audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Zydus Healthcare (USA) LLC. as of December 31, 2017 and 2016, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Ram Associates

Ram Associates
Hamilton, NJ

April 14, 2018

ZYDUS HEALTHCARE (USA) LLC

Balance Sheets

December 31,

ASSETS

	<u>2017</u>	<u>2016</u>
Current assets :		
Cash	\$ 342,470	\$ 352,921
Accounts receivable	256,451	316,425
Other current assets	<u>55,865</u>	<u>57,095</u>
Total current assets	654,786	726,441
Property and equipment, net	152,500	37,967
Building	1,441,655	1,484,055
Land	<u>665,000</u>	<u>665,000</u>
TOTAL ASSETS	<u><u>\$ 2,913,941</u></u>	<u><u>\$ 2,913,463</u></u>

LIABILITIES AND MEMBER'S EQUITY

Current liabilities :		
Accounts payable and accrued expenses	\$ 12,764	\$ 16,735
Other current liabilities	<u>6,592</u>	<u>3,000</u>
Total current liabilities	19,356	19,735
Long-term liabilities		
Loan from related party	<u>2,500,000</u>	<u>2,500,000</u>
Total current and long-term liabilities	<u>2,519,356</u>	<u>2,519,735</u>
Member's equity		
Members' capital	200,000	200,000
Retained earnings	<u>194,585</u>	<u>193,728</u>
Total member's equity	<u>394,585</u>	<u>393,728</u>
TOTAL LIABILITIES AND MEMBER'S EQUITY	<u><u>\$ 2,913,941</u></u>	<u><u>\$ 2,913,463</u></u>

- See accompanying notes to financial statements -

ZYDUS HEALTHCARE (USA) LLC

Statements of Income

For the years ended December 31,

	<u>2017</u>	<u>2016</u>
Net sales	\$ 145,619	\$ 172,452
Service charges	<u>69,538</u>	<u>92,517</u>
Net revenue	215,157	264,969
Cost of sales	<u>164,113</u>	<u>196,578</u>
Gross profit	51,044	68,391
Operating expenses		
General and administrative expenses	<u>18,104</u>	<u>15,932</u>
Operating income before other income / (expenses)	32,940	52,459
Other income / (expenses)		
Other income	189,165	154,941
Interest expense	(150,000)	(150,000)
Depreciation	<u>(63,383)</u>	<u>(49,332)</u>
Operating income before income taxes	8,722	8,068
Income taxes	<u>7,865</u>	<u>2,821</u>
Net income	<u>\$ 857</u>	<u>\$ 5,247</u>

- See accompanying notes to financial statements -

ZYDUS HEALTHCARE (USA) LLC

Statements of Changes in Member's Equity

For the years ended December 31, 2017 and 2016

	Member's equity	Retained earnings	Total member's equity
Balance at December 31, 2015	\$ 200,000	188,481	\$ 388,481
Net income		5,247	5,247
Balance at December 31, 2016	\$ 200,000	193,728	\$ 393,728
Net income		857	857
Balance at December 31, 2017	\$ 200,000	194,585	\$ 394,585

- See accompanying notes to financial statements -

ZYDUS HEALTHCARE (USA) LLC
Statements of Cash Flows
For the Years Ended December 31,

	2017	2016
Cash flows from operating activities		
Net income	857	\$ 5,247
Adjustment to reconcile net income to net cash provided by (used in) operating activities		
Depreciation	63,383	49,332
Changes in assets and liabilities :		
(Increase) / decrease in :		
Accounts receivable	59,974	(164,178)
Other current assets	1,230	821
Increase / (decrease) in :		
Accounts payable and accrued expenses	(3,971)	(25,154)
Other current liabilities	3,592	-
Total adjustments	124,208	(139,179)
Net cash provided by (used in) operating activities	125,065	(133,932)
Cash flows from investing activities		
Capital expenditures	(135,517)	(36,262)
Net cash provided by (used in) investing activities	(135,517)	(36,262)
Net (decrease) / increase in cash	(10,452)	(170,194)
Cash at the beginning of the year	352,921	523,115
Cash at the end of the year	\$ 342,470	\$ 352,921
Supplementary disclosure of cash flows information		
Cash paid during the year for :		
Income tax	\$ 3,000	\$ 4,500
Interest	150,000	150,000

- See accompanying notes to financial statements -

ZYDUS HEALTHCARE (USA) LLC

NOTES TO FINANCIAL STATEMENTS

For the Years ended December 31, 2017 and 2016

1) Organization and Description of Business

Zydus Healthcare USA LLC (ZHUL) was incorporated in Delaware on September 24, 2002. Subsequently ZHUL also registered its business in New Jersey on November 6, 2002. It is a wholly owned subsidiary of Cadila Healthcare Limited, India, ("Zydus Cadila"). Cadila Healthcare Limited, India purchased all the outstanding shares of the Company on March 23, 2017 from its previous owner Zydus International Private Limited, Ireland (100% subsidiary of Cadila Healthcare Limited) and effective from this date Zydus Cadila became the sole owner of the Company. Zydus Cadila manufactures and distributes prescription, over-the-counter and bulk Active Pharmaceutical Ingredients. ZHUL procures products from third parties and sells goods and services to Zydus Cadila.

The Company moved its corporate office to a new facility located at Pennington, New Jersey in 2010. Major portion of the facility was leased to Zydus Pharmaceuticals (USA), Inc, a related party.

2) Summary of Significant Accounting Policies

Accounting Policies

These financial statements are prepared on the accrual basis of accounting in conformity with accounting principles generally accepted in the United States of America ("GAAP"); consequently, revenue is recognized when services are rendered and expenses reflected when costs are incurred.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and use assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates are often based on judgments, probabilities and assumptions that management believes are reasonable but that are inherently uncertain and unpredictable. As a result, actual result could differ from those estimates.

ZYDUS HEALTHCARE (USA) LLC

NOTES TO FINANCIAL STATEMENTS

For the Years ended December 31, 2017 and 2016

Management periodically evaluates estimates used in the preparation of the consolidated financial statements for continued reasonableness. Appropriate adjustment, if any, to the estimates used are made prospectively based on such periodic evaluations.

Revenue Recognition

The Company recognizes product sales revenue when the title and risk of loss have transferred to the customers, when estimated provisions for product returns, rebates and other sales allowances are reasonably determinable, and when collectibles are reasonably assured. Accruals for these provisions are presented as reductions to revenues.

Accounts Receivables

Accounts receivable from Zydus Cadila, its parent Company on December 31, 2017 and 2016 were \$ 58,435 and \$ 110,948 respectively.

Accounts Payables and Other Current Liabilities

Accounts payables to Zydus Cadila, its parent Company on December 31, 2017 and 2016 were \$ Nil and \$ Nil respectively.

Credit and Business Concentration

The Company's financial instruments that are exposed to concentration of credit risks consist primarily of cash and cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to significant credit risk on cash and cash equivalents. Concentration of credit risks with respect to accounts receivable are limited because of the credit worthiness of the Company's major customers. 100% and 100% of the sales for 2017 and 2016 (towards goods and service charges) were made to Zydus Cadila its parent Company or to a related party under the group.

ZYDUS HEALTHCARE (USA) LLC

NOTES TO FINANCIAL STATEMENTS

For the Years ended December 31, 2017 and 2016

Property and Equipment

Property and equipment are stated at cost. Depreciation is provided for in amounts sufficient to relate the cost of depreciable assets to operations over their estimated useful lives by the straight-line method. Depreciation of an asset commences when the asset is put into use. The estimated useful lives of the related assets range from 3 to 39.5 years.

Property and equipment consists of the followings as of December 31:

	2017	2016
Computer Equipment	\$ 42,889	\$ 41,143
Furniture and Fixture	81,644	65,801
Machinery and Equipment	156,546	42,728
Building	1,802,245	1,799,085
Land	665,000	665,000
Fixed Asset in Transit	950	-
	<u>2,749,274</u>	<u>2,613,757</u>
Less : Accumulated Depreciation	490,119	426,735
Net Assets	<u>\$ 2,259,155</u>	<u>\$ 2,187,022</u>

The Company charges repairs and maintenance costs that do not extend the lives of the assets, to expenses as incurred.

Depreciation expenses during the years ended December 31, 2017 and 2016 were \$ 63,383 and \$ 49,332 respectively.

3) Pension Plan

ZHUL has implemented an Employer sponsored 401K Pension plan effective October 1, 2003. The Company has merged its 401K plan with the 401K plan of Zydus Pharmaceuticals USA Inc effective from April 1, 2010. Under the plan, ZHUL will make Qualified-matching contribution to a maximum of 5% of the basic pay of the eligible employees. All qualified matching contributions are 100% vested and are subject to certain withdrawal

ZYDUS HEALTHCARE (USA) LLC

NOTES TO FINANCIAL STATEMENTS

For the Years ended December 31, 2017 and 2016

restrictions. For the years ended December 31, 2017 and 2016, ZHUL made a matching contribution of \$22,719 and \$18,875 respectively.

4) Related Party Transactions

a. Sales to Zydus Cadila - parent Company, towards sale of goods is as follows:

	<u>December 31,</u>	
	<u>2017</u>	<u>2016</u>
Sale of goods	\$ 145,619	\$ 172,322
Total	<u>\$ 145,619</u>	<u>\$ 172,322</u>

b. During the years 2017 and 2016 Cadila - parent Company reimbursed agreed expenses incurred by ZHUL, along with a service charges as follows:

	<u>December 31,</u>	
	<u>2017</u>	<u>2016</u>
Expense	\$ 614,814	\$ 621,101
Service charges	43,390	74,531
Total,	<u>\$ 658,204</u>	<u>\$ 695,632</u>

c. During the years ended December, 2017 and 2016 Zydus Discovery DMCC a related party, reimbursed agreed expenses incurred by ZHUL, along with a service charges as follows:

	<u>December 31,</u>	
	<u>2017</u>	<u>2016</u>
Expense	\$ 281,101	\$ 148,973
Service charges	26,148	17,986
Total,	<u>\$ 307,249</u>	<u>\$ 167,859</u>

ZYDUS HEALTHCARE (USA) LLC

NOTES TO FINANCIAL STATEMENTS

For the Years ended December 31, 2017 and 2016

5) Income Taxes

The Company records income taxes using the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and the tax effect of net operating loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company files income tax returns in the U.S. federal jurisdiction, and various State jurisdictions. The Company is generally subject to U.S. Federal, State and local examinations by tax authorities for the last three years.

6) Commitments

The Company borrowed a sum of \$2,500,000 at the rate of 6% per annum from Zydus Pharmaceuticals USA Inc, a related Company. The term of the loan is thirty (30) years. This loan is payable in three hundred fifty nine (359) monthly payments of interest only in the amount of Twelve Thousand Five Hundred Dollars (\$12,500) payable on the fifteenth day of each month, and a final payment of all principal plus accrued interest due, fees and other changes payable on January 5, 2040 (the "Maturity Date").

7) New Accounting Pronouncements

i) On November 17, 2016, the FASB issued ASU 2016-18, *Statement of Cash Flows (Topic 230): Restricted Cash*. It is intended to reduce diversity in the presentation of restricted cash and restricted cash equivalents in the statement of cash flows. The new standard requires that restricted cash and restricted cash equivalents be included as components of total cash and cash equivalents as presented on the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 is effective for annual periods beginning after

ZYDUS HEALTHCARE (USA) LLC

NOTES TO FINANCIAL STATEMENTS

For the Years ended December 31, 2017 and 2016

December 15, 2017 including interim periods within those fiscal years. Earlier adoption is permitted.

ii) In January 2017, the FASB issued Accounting Standards Update No. 2017-01, *Clarifying the Definition of a Business*, which clarifies and provides a more robust framework to use in determining when a set of assets and activities is a business. The amendments in this update should be applied prospectively on or after the effective date. This update is effective for annual periods beginning after December 15, 2017, and interim periods within those periods. Early adoption is permitted for acquisition or deconsolidation transactions occurring before the issuance date or effective date and only when the transactions have not been reported in issued or made available for issuance financial statements. The Company does not expect the adoption to have any significant impact on its Financial Statements.

iii) In January 2017, the FASB issued ASU No. 2017-04, *Simplifying the Test for Goodwill Impairment*. Under the new standard, goodwill impairment would be measured as the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying value of goodwill. This ASU eliminates existing guidance that requires an entity to determine goodwill impairment by calculating the implied fair value of goodwill by hypothetically assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted for interim or annual goodwill impairment test performed on testing dates after January 1, 2017.

8) SUBSEQUENT EVENTS

In accordance with FASB ASC 855, the Company has evaluated subsequent events through April 14, 2018, the date these financial statements were issued. No reportable subsequent events have occurred through April 14, 2018 which would have a significant effect on the financial statements as of December 31, 2017, except as otherwise disclosed.